In line with Recommendation 3, the results of the APT trial established adjuvant paclitaxel and trastuzumab as the preferred standard therapy in patients with small (≤3 cm), node-negative HER2+ breast cancer following surgery and locoregional radiotherapy, if indicated. The gene discussed is ERBB2; the disease is breast carcinoma.